Head and neck squamous cell carcinoma (HNSCC)
Conditions
Brief summary
• Dose-activity curves for healthy organs, • Tumour: background ratio at different timepoints post-injection, • AEs until 30 days post-injection, • Correlation between standardised uptake value of [18F]-olaparib in tumour lesions, and PARP1 expression levels determined by immunohistochemistry
Detailed description
• Absolute and percentage increase in tumour [18F]-olaparib standardised uptake value after one week of chemoradiation compared to baseline tumour [18F]-olaparib standardised uptake value., • Correlation between standardised uptake value of [18F]-olaparib in tumour lesions, and PARP1 expression levels determined by immunohistochemistry after one week of chemoradiation.
Interventions
None listed
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Dose-activity curves for healthy organs, • Tumour: background ratio at different timepoints post-injection, • AEs until 30 days post-injection, • Correlation between standardised uptake value of [18F]-olaparib in tumour lesions, and PARP1 expression levels determined by immunohistochemistry | — |
Secondary
| Measure | Time frame |
|---|---|
| • Absolute and percentage increase in tumour [18F]-olaparib standardised uptake value after one week of chemoradiation compared to baseline tumour [18F]-olaparib standardised uptake value., • Correlation between standardised uptake value of [18F]-olaparib in tumour lesions, and PARP1 expression levels determined by immunohistochemistry after one week of chemoradiation. | — |
Countries
Netherlands
Outcome results
None listed